Dovitinib
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Malignant Pleural Mesothelioma
Conditions
Advanced Malignant Pleural Mesothelioma, MPM
Trial Timeline
Mar 1, 2013 → Jun 1, 2015
NCT ID
NCT01769547About Dovitinib
Dovitinib is a phase 2 stage product being developed by Novartis for Advanced Malignant Pleural Mesothelioma. The current trial status is terminated. This product is registered under clinical trial identifier NCT01769547. Target conditions include Advanced Malignant Pleural Mesothelioma, MPM.
What happened to similar drugs?
16 of 20 similar drugs in Advanced Malignant Pleural Mesothelioma were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (11)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01888965 | Phase 2 | Terminated |
| NCT01732107 | Phase 2 | Terminated |
| NCT01769547 | Phase 2 | Terminated |
| NCT01676714 | Phase 2 | Completed |
| NCT01753713 | Phase 2 | Completed |
| NCT01266070 | Phase 2 | Terminated |
| NCT01678105 | Phase 2 | Completed |
| NCT01719549 | Phase 2 | Completed |
| NCT01791387 | Phase 2 | UNKNOWN |
| NCT01262027 | Phase 2 | Completed |
| NCT01443481 | Phase 1 | Completed |
Competing Products
20 competing products in Advanced Malignant Pleural Mesothelioma